Conbercept

The Age-Related Macular Degeneration (AMD) Drugs Market is projected to reach USD 17.37 Billion by 2029, growing from USD 10.46 Billion in 2024 at a CAGR of 10.7%. Factors driving growth include an aging population, lifestyle factors, and rising incidences of AMD. Vabysmo is expected to show the highest growth due to positive feedback and efficacy. Hospitals will witness high growth as end users. Biologics will dominate the approval type segment. North America is the fastest-growing region. Key companies profiled include Regeneron Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd, and Novartis AG.